544184

- Borosil Scientific Limited allotted 4,475 equity shares on August 13, 2026, upon exercise of vested stock options under its ESOP scheme at an exercise price of ₹141 per share. These shares rank pari-passu with existing equity shares. The total issued and paid-up equity share capital now stands at 8,89,51,525 equity shares of Re. 1/- each.

- Consolidated Revenue ₹106.75Cr vs ₹95.98Cr (▲11.23% YoY) - EBITDA ₹10.87Cr vs ₹7.41Cr (▲46.72% YoY) - PAT ₹4.36Cr vs ₹(4.21)Cr (Turned profitable from a loss YoY) - EBITDA Margin 10.18% vs 7.72% (▲246bps)

- Consolidated Revenue ₹10,675.23 Lakhs vs ₹9,597.64 Lakhs (▲11.23% YoY) - EBITDA ₹1,112.27 Lakhs vs ₹779.10 Lakhs (▲42.76% YoY) - PAT attributable to owners ₹437.08 Lakhs for Q1 FY27 compared to a loss of ₹(416.43) Lakhs in Q1 FY26 (YoY turnaround from loss to profit) - EBITDA Margin 10.42% vs 8.12% (▲230bps) - The Board also approved modifications to ESOP schemes, increasing the maximum discount limit for new options from 10% to 20%.

- Board meeting on August 3, 2026, to approve Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. - Trading window for designated persons remains closed until 48 hours after results declaration.

New Filing detected. See link for details.

- Borosil Scientific Limited responded to BSE's query regarding an increase in its security's price/volume. - The company confirmed it has not withheld any material information/event that requires disclosure under SEBI regulations. - The increase in price/volume is attributed to market-driven factors.

- Intimation of Closure of Trading Window for Borosil Scientific Limited. - Trading window to remain closed for Designated Persons and their immediate relatives from July 01, 2026. - Closure is for the declaration of Un-audited Financial Results (Standalone & Consolidated) for the quarter ending June 30, 2026. - The window will reopen 48 hours after the declaration of results.

Borosil Scientific Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms the company's full compliance with all applicable SEBI Regulations, including LODR, ICDR, SAST, and Insider Trading Regulations, and Secretarial Standards. It highlights no disqualification of directors, no resignation of statutory auditors, and no regulatory actions by SEBI or Stock Exchanges during the review period.

Borosil Scientific Limited's Nomination and Remuneration Committee approved the grant of 18,700 employee stock options on May 20, 2026. Each option, priced at ₹108 (approximately 10% discount to the market price), entitles the holder to one equity share of Re. 1/-. The options will vest 25% annually over four years from the grant date, with an exercise period of five years from vesting.